Samsung Bioepis Announces Regular Executive Promotions: 2 Vice Presidents, 4 Executive Directors

by Jeong Donghoon

Published 25 Nov.2025 14:07(KST)

Samsung Bioepis announced on November 25 that it had promoted a total of six executives, including two Vice Presidents and four Executive Directors, under its performance- and competency-based HR principles. The promotions focused on next-generation leaders who have contributed to the company through outstanding achievements and are expected to drive future innovation.

Donghoon Shin, who was promoted to Vice President and Head of Development Division 2, was born in 1974 and is a clinical medicine expert with a background as a medical doctor. Leveraging his experience in biosimilar clinical trial design, medical review, and consulting, he has established clinical and regulatory strategies for new drug development.

Donghoon Shin, Vice President, and Jieun Shin, Vice President, Samsung Bioepis

Jieun Shin, promoted to Vice President and Head of the MSAT (Manufacturing Science & Technology) Team in Development Division 1, was born in 1981 and is a development specialist with expertise in process development and technology transfer. She has enhanced product competitiveness through production process optimization and by identifying new partners.

Sung-Hoon Son, Executive Director and Head of the Legal Group, was born in 1975 and is an overseas attorney with expertise in intellectual property (IP). He has provided swift support for patent applications and legal reviews, managed numerous global IP litigations, and contributed to the timely launch of products.

So-Shin Ahn, promoted to Executive Director and Head of the Clinical Development Group in the Product Evaluation (PE) Team, was born in 1980 and is a translational medicine expert. She established the nonclinical new drug development process and led the clinical design for new drug development.

Sung-Hoon Son, So-Shin Ahn, Nam-Hoon Lee, Jeong-Han Jeong. Samsung Bioepis

Nam-Hoon Lee, Executive Director and Head of the Business Strategy Group in the Strategy Team, is a business planning expert with diverse experience in strategy development and supply chain management (SCM). He led the transition to a holding company structure and contributed to the development of strategies for new bio businesses.

Jeong-Han Jeong, Executive Director and Head of the RA3 Group in the Regulatory Affairs (RA) Team, was born in 1987 and is an expert in product regulatory approvals. He expanded the number of countries where products are approved, laying the foundation for increased sales, and contributed to shortening biosimilar development timelines and reducing costs.

Samsung Bioepis stated, "Based on talented individuals with growth potential and expertise, we will continue to advance as a leading company in the global biopharmaceutical industry and pursue sustainable growth."

The following is the list of promoted executives.

◆ Vice President Promotions

▲Donghoon Shin ▲Jieun Shin